

Protein-Protein Interactions: Unraveling the link between HTLV-1 Tax-1 oncoprotein and human *Drosophila discs large* tumor suppressor




Wael El Yazidi Mouloud¹, Sibusiso B. Maseko², Yasmine Brammerloo², Inge Van Molle³,
Adria Sogues Castrejon³, Charlotte Martin¹, Han Remaut³, Steven Ballet¹, Oleksandr Volkov^{3,4},
Jean-Claude Twizere^{2,5,6}

¹ Research Group of Organic Chemistry – Vrije Universiteit Brussel (VUB) – Brussels (BE)
² Laboratory of Viral Interactomes, Unit of Molecular Biology of Diseases, GIGA Institute – University of Liege – Liège (BE)
³ VIB-VUB Center for Structural Biology, Flemish Institute of Biotechnology (VIB) – Brussels (BE)
⁴ Jean Jeener NMR Centre – Brussels (BE)
⁵ TERRA research and teaching centre, Microbial Processes and Interactions (MIPI), Gembloux Agro Bio-tech – University of Liege – Liège (BE)
⁶ Laboratory of Algal Synthetic and Systems Biology, Division of Science and Math – New York University of Abu Dhabi – Abu Dhabi (UAE)

e-mail: wael.el.yazidi.mouloud@vub.be

INTRODUCTION [I]


Tax-1 is the most pathogenic protein of the human T-cell leukemia virus type 1 (HTLV-1), an oncogenic virus responsible for the onset of an aggressive form of cancer, adult T-cell leukemia (ATL). The oncoprotein undergoes protein-protein interactions (PPI) with a plethora of host proteins, such as the human homologue of the *Drosophila discs large* (hDlg1) tumor suppressor which is implicated in HTLV-1's oncogenic abilities.¹ This study aimed at the characterization of the interaction between HTLV-1 Tax-1 and hDlg1 PDZ domains.²




The interaction was characterized through nuclear magnetic resonance (NMR) and X-ray crystallography, additionally isothermal titration calorimetry (ITC) was utilized to quantify the strength of the respective interactions. Our work provides structural insights essential in the pursuit of PPI inhibitors.

X-RAY CRYSTALLOGRAPHY [III]

PDZ1 co-crystallization




PDZ2 co-crystallization



Residues experiencing the largest spectral changes in NMR (G235, F236 and S237 for PDZ1 & G330, F331 and S332 for PDZ2) are accounted for in the crystal structure.

Binding observed in the crystal structure is compatible with the measured spectral changes by solution NMR.

ISOTHERMAL TITRATION CALORIMETRY [IV]



Both interactions are enthalpically driven, with the decamer binding stronger to PDZ2.

CONCLUSIONS [V]



- Solution NMR revealed the binding hotspots to be located in the β1/β2 loop, β2 strand and α2 helix.
- Only the last four amino acids (H-Glu-Thr-Glu-Val-OH) of the Tax-1 10-mer seem to be essential for the binding.
- Tetramer bound PDZ domains crystals revealed a binding modality congruent with the hotspots observed by NMR.

PERSPECTIVES [VI]

- Structural insights gained by X-ray crystallography and NMR could be utilized to find potential PPI inhibitors (small molecules and peptides).


NUCLEAR MAGNETIC RESONANCE [II]

PDZ domains predominantly interact with the C-terminal tail of their binding partners, appropriately called PDZ-binding motif (PBM),³ thus a similar interaction was expected with Tax-1. Peptides mimicking the C-terminal tail of the Tax-1 protein were synthesized and their respective interactions with the PDZ domains was evaluated through [¹H,¹⁵N] heteronuclear single-quantum correlation (HSQC).





Significant spectral changes for residues located in β1/β2 loop, β2 strand and α2 helix

Individual domains



Highly similar binding modalities between the tandem and the individual domains.
Residues G235, F236, G330 and F331 experience the largest spectral changes.

Essential amino acids



When split in two parts, only the last four amino acids cause spectral changes

H-Glu-Thr-Glu-Val-OH is the essential part for the interaction.

ACKNOWLEDGEMENTS

We thank the Research Council of the VUB for financial support through the Strategic Research Programmes (SRP50 & SRP95), the Research Foundation Flanders (FWO) through FWO Hercules (OZR3939) and the Fund for Scientific Research (FNRS) for the financial support.

REFERENCES

- Suzuki, T.; Ohsugi, Y.; Uchida-Toita, M.; Akiyama, T.; Yoshida, M. *Oncogene*. **1999**, *18* (44), 5967-5972
- Maseko, S. B.; Brammerloo, Y.; Van Molle, I.; Sogues, A.; Martin, C.; Gorgulla, C.; Olivet, J.; Blavier, J.; Ntombela, T.; Delvigne, F.; Arthanari, H.; Salehi-Ashtiani, K.; Remaut, H.; Ballet, S.; Volkov, A., N.; Twizere, J. *Antiviral Research*. **2023**, *217*, 105675
- Songyang, Z.; Fanning, A. S.; Fu, C.; Xu, J.; Marfatia, S. M.; Chishti, A., H.; Crompton, A.; Chan, A., C.; Anderson, J., M.; Cantley, L., C. *Science*. **1997**, *275* (5296), 73-77